Roger Goldberg, M.D., Joins Kiora Pharmaceuticals' Scientific Advisory Board

Encinitas, California – June 25, 2024 – Kiora Pharmaceuticals (NASDAQ: KPRX) has added Roger A. Goldberg, MD, MBA, a vitreoretinal surgeon with Bay Area Retina Associates (BARA), to its Scientific Advisory Board. Dr. Goldberg is expected to provide valuable scientific and clinical expertise to support Kiora's mission of developing innovative treatments for retinal diseases.

Dr. Goldberg brings a wealth of clinical experience in retinal disease, emphasizing the pressing need for new and improved treatments that can alter the course of vision-threatening conditions. He highlighted Kiora's investigational drug, KIO-104, which targets overactive immune cells implicated in various retinal diseases such as macular edema, uveitis, and inflammation-related vision impairment. Dr. Goldberg expressed enthusiasm about contributing to Kiora's advancements, aiming to benefit as many patients as possible through their innovative technologies.

Dr. Goldberg has an extensive background as an investigator in numerous interventional retinal therapeutic clinical trials. His research work appears in prominent medical journals like The New England Journal of Medicine, Ophthalmology, JAMA Ophthalmology, and the American Journal of Ophthalmology (AJO). He also reviews for AJO and Retina and frequently participates as faculty in national and international meetings. Furthermore, Dr. Goldberg co-founded Emmecell, a biotechnology firm focusing on regenerative, cell-based therapies for eye diseases, where he serves on the board of directors.

Eric Daniels, MD, MBA, Chief Development Officer of Kiora, underscored the strategic significance of Dr. Goldberg's vast research background and clinical knowledge. Dr. Daniels noted that Dr. Goldberg’s insights would be instrumental in enhancing Kiora’s efforts to discover and develop new treatment options for various ophthalmic conditions. He emphasized that retinal inflammation drives vision loss in numerous sight-threatening diseases, and Dr. Goldberg's expertise will be crucial in optimizing the development of KIO-104 as a potential groundbreaking treatment for millions of patients globally.

Dr. Goldberg's educational journey includes degrees from Yale University and a residency at the Bascom Palmer Eye Institute in Miami, a leading eye hospital and training program. He further specialized with a fellowship in Vitreoretinal Diseases and Surgery at Tufts University and Ophthalmic Consultants of Boston. Certified by the American Board of Ophthalmology, Dr. Goldberg actively participates in several prestigious organizations, including the American Society of Retinal Specialists, the Retina Society, the Association for Research in Vision and Ophthalmology, and the American Academy of Ophthalmology.

Joining Kiora’s Scientific Advisory Board, Dr. Goldberg will collaborate with other distinguished experts such as:
- Dr. Robert Casson, MD, PhD, Consultant Ophthalmologist at the Royal Adelaide Hospital and Head of the Ophthalmic Research Lab at the University of Adelaide.
- Dr. Allen Ho, MD, Director of Research at the Wills Eye Hospital, Professor of Ophthalmology at Thomas Jefferson University, and partner of Mid Atlantic Retina.
- Dr. Christine Kay, MD, PhD, Inherited Retinal Disease specialist at Vitreoretinal Associates in Gainesville, FL, and Affiliate Assistant Professor at the University of South Florida.
- Dr. Mark Pennesi, MD, PhD, Director of Ophthalmic Genetics at Retina Foundation of the Southwest.
- Dr. Russell Van Gelder, MD, PhD, Chairman of the Department of Ophthalmology at the University of Washington.
- Dr. Charles Wykoff, MD, PhD, Director of Research at the Retina Consultants of Texas, and Chairman of the Research and Clinical Trials Subcommittee at the Retina Consultants of America.

About Kiora Pharmaceuticals
Kiora Pharmaceuticals is a biotech company focusing on developing and commercializing treatments for orphan retinal diseases. Their lead product, KIO-301, is being developed for conditions like retinitis pigmentosa, choroideremia, and Stargardt disease. KIO-104 is aimed at treating posterior non-infectious uveitis, acting as a non-steroidal, immuno-modulatory small-molecule inhibitor of dihydroorotate dehydrogenase.